Advertisement
Screener

SELLAS Life Sciences Group, Inc. (SLS) Unamortized Debt Issuance Expense

2.8 / 5 stars · 68/120 Roast Me

SELLAS Life Sciences Group, Inc. Unamortized Debt Issuance Expense

SELLAS Life Sciences Group, Inc. (SLS) had Unamortized Debt Issuance Expense of -$485.00 thousand as of 2015-12-31, per its 10-K/A filed 2016-04-15.

Discontinued › Balance Sheet › Assets › Assets, Noncurrent

us-gaap:UnamortizedDebtIssuanceExpense · last filed 2016-04-15

  • 2015-12-31: Unamortized Debt Issuance Expense -$485.00K.
  • 2014-12-31: Unamortized Debt Issuance Expense -$238.00K.
  • 2013-12-31: Unamortized Debt Issuance Expense $108.00K.
Period endUnamortized Debt Issuance Expense
2015-12-31-$485.00K
10-K/A · filed 2016-04-15
2014-12-31-$238.00K
8-K · filed 2015-12-04
2013-12-31$108.00K
10-K · filed 2014-03-17

Similar stocks

Stock NameCountryMarket CapPE Ratio
uniQure N.V. (QURE)$2.416B-4.93
Vera Therapeutics, Inc. (VERA)United States$2.402B-7.67
Harmony Biosciences Holdings, Inc. (HRMY)United States$2.399B11.67
Nurix Therapeutics, Inc. (NRIX)United States$2.457B-5.39
Mineralys Therapeutics, Inc. (MLYS)United States$2.353B-6.82
Viridian Therapeutics, Inc.\DE (VRDN)United States$2.342B-5.38
SUPERNUS PHARMACEUTICALS, INC. (SUPN)United States$2.517B-24.63
Immunome Inc. (IMNM)United States$2.538B-9.45
Disc Medicine, Inc. (IRON)United States$2.553B-11.40
Zai Lab Ltd (ZLAB)$2.241B-113.34